ACM
LXRX icon

Aquatic Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Aquatic Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,000
Closed -$8K – 1546
2022
Q4 		$8K Buy
+4,000
New +$8.51K ﹤0.01% 1227

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's LXRX Position: Q1 2023 in Review

Aquatic Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2023, closing a stake of 4,000 shares — an estimated $8K sold.

Aquatic Capital Management first reported a position in LXRX in Q4 2022 and held it in 1 quarter. The position peaked at $8K in Q4 2022. 104 funds tracked by Wall St. Rank hold LXRX as of Q1 2023.

  • Aquatic Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 4,000 Lexicon Pharmaceuticals shares in Q1 2023, an estimated $8K.
  • Aquatic Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Aquatic Capital Management's Lexicon Pharmaceuticals position peaked at $8K in Q4 2022.
  • 104 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2023.

Based on Aquatic Capital Management's 13F filing for Q1 2023, filed 15 May 2023.